Arkolith/Insider Trading/ABUS/Form 4

Manchester Keith S

DirectorArbutus Biopharma Corp (ABUS) · full profile →Form 4 · filed Aug 16, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$33K
Net Open-Market Flow
-$33K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 14, 2024Sell(S)9K$3.69$33K46K
Aug 14, 2024Option exercise(M)55K$0.56$31K55K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 14, 2024Option exercise(M)55K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001447028-24-000078) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML